Food4, >> to the moon <<
Lol, Yes we all learned the hard way not to get our hopes up too much, and that's true with any of these bio stocks. So instead of 'to the moon', I'll be happy to get to the '2nd floor' :o)
I don't have plans to take a position, but around the time of the recapitalization might be a time to consider it. I figure the CX-1739 RD results will likely be released in the period before the RS-reverse split, and they'll probably announce a financing associated with the R/S. So an investor might be able to get in near the price of the financing entity, albeit without the warrants. Then there should be continued positive anticipation over the Dronabinol results, which I figure will be released in the Fall (just a guess), and that positive vibe will keep the share price from falling back after the R/S.
But how events actually unfold is anyone's guess. It's fun following these bios without having a financial stake since you get most of the excitement but without the ulcers.
Ultimately the clinical trial results will decide where the stock goes. The previous RD trial showed clear efficacy at the high dose, even though there were some technical difficulties that negated the middle dose cohort's data. That trial used CX-717 rather than CX-1739, but one would expect similar or better results since they're both low impacts and CX-1739 is actually 3X more potent than CX-717. We've seen that respiratory trials can be somewhat tricky to run, but assuming no significant technical/procedural problems, there is good reason to expect positive results.
With Dronabinol, the previous Phase 2a (Pier Pharma) appeared to have good results, so hopefully those will be validated in this larger trial. I'm mainly interested in the Ampakine side though.
News 
Market Data 
Discover 
